Egypt's state-owned Drug Holding Company (HoldiPharma) has entered into a joint venture with US-based Dawah Pharmaceuticals to manufacture and export pharmaceutical products and nutritional supplements to international markets, with an initial focus on North America and Europe, the Egyptain Cabinet said Wednesday. Under the agreement, HoldiPharma will hold a 40 per cent stake in the new company, while Dawah Pharma will control the remaining 60 per cent. The venture aims to expand Egypt's pharmaceutical footprint globally, with exports managed through the new entity. Public Business Sector Minister Mohamed Sheemy said the partnership signals growing global recognition of the quality of Egyptian pharmaceuticals, especially those produced by HoldiPharma and its subsidiaries. He cited recent upgrades in production infrastructure and adherence to international Good Manufacturing Practices (GMP) as key enablers. The company will produce a range of pharmaceutical products, including ampoules, sterile injectables, ophthalmic solutions, over-the-counter (OTC) medications, and nutritional supplements. The first phase of the agreement includes exporting six nutritional supplement products to the US market—marking HoldiPharma's debut entry into the United States. The venture will also incorporate advanced manufacturing technologies, including pre-filled syringes, transdermal patches, tablets, and syrups. These capabilities are expected to boost exports and support the long-term growth of HoldiPharma and its affiliates. Minister Sheemy confirmed that the new company will operate in full compliance with international regulatory standards, including those of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), positioning Egyptian pharmaceuticals for broader market access in both developed and emerging economies. Attribution: Amwal Al Ghad English Subediting: Y.Yasser
